Parameters | Mean | Lower 95 % CI | Upper 95 % CI | Distribution | Source |
---|---|---|---|---|---|
Annual non-persistence probability | |||||
Denosumab | 0.098 | 0.05 | 0.15 | Log normal | [7] |
Alendronate | 0.202 | 0.14 | 0.28 | ||
Mortality relative risk (in 1st year after a fracture) | |||||
Hip fracture | 2.43 | 2.02 | 2.93 | Log normal | [17] |
Non-Hip fracture | 1.65 | 1.52 | 2.17 | ||
Annual costs | |||||
Denosumab (2 × 60 mg/mL) | $541.64 | PBS | |||
Administration | $24.0 | MBS | |||
Alendronate (52 × 70 mg) | $199.16 | PBS | |||
Annual follow-up | $148.5 | MBS | |||
Hip fracture, year 1 | $30,720 | $24,576 | $36,864 | Log normal | [2] |
Hip fracture, year 2+ | $3280 | $2624 | $3936 | ||
Non-hip fracture, year 1 | $6593 | $5274 | $7912 | ||
Non-hip fracture, year 2+ | $253 | $202 | $303 | ||
Utility values (no fracture) | |||||
Mean population value (age 70–80 years) | 0.8 | 0.78 | 0.82 | Beta | [21] |
Utility multipliers | |||||
Hip fracture, year 1 | 0.70 | 0.64 | 0.77 | Beta | |
Hip fracture, year 2+ | 0.80 | 0.68 | 0.96 | ||
Non-hip fracture, year 1 | 0.84 | 0.75 | 0.92 | ||
Non-hip fracture, year 2+ | 0.96 | 0.95 | 0.97 | ||
Fracture risk equations parameters | |||||
a [Constant coefficient for hip fractures] | 0.0005 | 0.0003 | 0.0007 | Probability weights assigned (based on χ2 statistic) | |
b [Prev. fracture coefficient for hip fractures] | 1.4979 | 1.2659 | 1.7379 | ||
c [Year coefficient for hip fractures] | 0.0699 | 0.0367 | 0.1031 | ||
d [(-BMD−1.98) coefficient for hip fractures] | 0.0267 | 0.0159 | 0.0367 | ||
e [Exponent of (-BMD−1.98) for hip fractures] | 1.5042 | 1.2651 | 1.7331 | ||
f [Constant coefficient for non-hip fractures] | 0.0043 | 0.0022 | 0.0069 | ||
g [Prev. fracture coefficient for non-hip fractures] | 1.4981 | 1.2631 | 1.7374 | ||
h [Year coefficient for non-hip fractures] | 0.0698 | 0.0369 | 0.1033 | ||
i [(-BMD−1.98) coefficient for non-hip fractures] | 0.1997 | 0.1377 | 0.2704 | ||
j [Exponent of (-BMD−1.98) for non-hip fractures] | 1.4218 | 1.2146 | 1.5913 |